BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Allarity Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Allarity Therapeutics\, Inc.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03878849-10856@assetmemo.bio
DTSTAMP:20261121T011044Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:stenoparib: Phase 2 readout est. (NCT03878849)
DESCRIPTION:stenoparib\, phase 2\, Ovarian Cancer.\nStudy: Investigation of
  the Anti-tumor Effect of 2X-121 in Patients With Recurrent\, Advanced Ova
 rian Cancer\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/stenoparib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03878849
URL:https://assetmemo.bio/drug/stenoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
